Cancer vaccines 2000

Immunology Letters

Volumn 74, Issue 1, 2000, Pages 1-3

  Tartour, E ^a   Fridman, W H ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOLOGY; CANCER PREVENTION; EDITORIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMAL; CANCER VACCINES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMAN; IMMUNOTHERAPY, ACTIVE; MICE; NEOPLASMS;

EID: 0034666259     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(00)00242-X     Document Type: Editorial

References (30)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Tamura Y., Peng P., Liu K., Daou M., Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:1997;117-120.
3. Ruiz P.J., Wolkowicz R., Waisman A., Hirschberg D.L., Carmi P., Erez N., Garren H., Herkel J., Karpuj M., Steinman L., Rotter V., Cohen I.R. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. 4:1998;710-712.
4. Pervin S., Chakraborty M., Bhattacharya-Chatterjee M., Zeytin H., Foon K.A., Chatterjee S.K. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res. 57:1997;728-734.
5. de Zoeten E.F., Carr-Brendel V., Cohen E.P. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells. J. Immunol. 160:1998;2915-2922.
6. Bloom M.B., Perry-Lalley D., Robbins P.F., Li Y., el-Gamil M., Rosenberg S.A., Yang J.C. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:1997;453-459.
7. Mandelboim O., Vadai E., Fridkin M., Katz-Hillel A., Feldman M., Berke G., Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1:1995;1179-1183.
8. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., Storkus W.J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:1996;87-97.
9. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60:2000;51-55.
10. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183-1187.
11. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:1997;558-561.
12. Falo L.D. Jr, Kovacsovics-Bankowski M., Thompson K., Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:1995;649-653.
13. Fayolle C., Ladant D., Karimova G., Ullmann A., Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J. Immunol. 162:1999;4157-4162.
14. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
15. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
16. Schlom J., Tsang K.Y., Kantor J.A., Abrams S.I., Zaremba S., Greiner J., Hodge J.W. Strategies in the development of recombinant vaccines for colon cancer. Semin. Oncol. 26:1999;672-682.
17. Sun Y., Jurgovsky K., Moller P., Alijagic S., Dorbic T., Georgieva J., Wittig B., Schadendorf D. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 5:1998;481-490.
18. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E.B., Steinman R.M., Enk A., Kampgen E., Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
19. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
20. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA. 92:1995;8078-8082.
21. Kugler A., Stuhler G., Walden P., Zoller G., Zobywalski A., Brossart P., Trefzer U., Ullrich S., Muller C.A., Becker V., Gross A.J., Hemmerlein B., Kanz L., Muller G.A., Ringert R.H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:2000;332-336.
22. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
23. Tjoa B.A., Simmons S.J., Elgamal A., Rogers M., Ragde H., Kenny G.M., Troychak M.J., Boynton A.L., Murphy G.P. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 40:1999;125-129.
24. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M., Putnam J.B., Schea R., Shin D.M., Walsh G.L., Dolormente M.M., Han C.I., Martin F.D., Yen N., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay T., Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:1996;985-991.
25. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
26. Bendandi M., Gocke C.D., Kobrin C.B., Benko F.A., Sternas L.A., Pennington R., Watson T.M., Reynolds C.W., Gause B.L., Duffey P.L., Jaffe E.S., Creekmore S.P., Longo D.L., Kwak L.W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 10:1999;1171-1177.
27. Mackiewicz A., Gorny A., Laciak M., Malicki J., Murawa P., Nowak J., Wiznerowicz M., Hawley R.G., Heinrich P.C., Rose-John S. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum. Gene Ther. 6:1995;805-811.
28. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K.K., Cosimi A.B., Duda R., Sober A., Bhan A., Daley J., Neuberg D., Parry G., Rokovich J., Richards L., Drayer J., Berns A., Clift S., Dranoff G. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 95:1998;13141-13146.
29. Fernandez N.C., Levraud J.P., Haddada H., Perricaudet M., Kourilsky P. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J. Immunol. 162:1999;609-617.
30. Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today. 14:1993;536-538.